Comprehensive analysis of human microRNA target networks

Jun-ichi Satoh* and Hiroko Tabunoki

* Correspondence: satoj@my-pharm.ac.jp
Department of Bioinformatics and Molecular Neuropathology, Meiji Pharmaceutical University, 2-522-1 Noshio, Kiyose, Tokyo 204-8588, Japan

Abstract

Background: MicroRNAs (miRNAs) mediate posttranscriptional regulation of protein-coding genes by binding to the 3’ untranslated region of target mRNAs, leading to translational inhibition, mRNA destabilization or degradation, depending on the degree of sequence complementarity. In general, a single miRNA concurrently downregulates hundreds of target miRNAs. Thus, miRNAs play a key role in fine-tuning of diverse cellular functions, such as development, differentiation, proliferation, apoptosis and metabolism. However, it remains to be fully elucidated whether a set of miRNA target genes regulated by an individual miRNA in the whole human microRNAome generally constitute the biological network of functionally-associated molecules or simply reflect a random set of functionally-independent genes.

Methods: The complete set of human miRNAs was downloaded from miRBase Release 16. We explored target genes of individual miRNA by using the Diana-microT 3.0 target prediction program, and selected the genes with the miTG score ≥ 20 as the set of highly reliable targets. Then, Entrez Gene IDs of miRNA target genes were uploaded onto KeyMolnet, a tool for analyzing molecular interactions on the comprehensive knowledgebase by the neighboring network-search algorithm. The generated network, compared side by side with human canonical networks of the KeyMolnet library, composed of 430 pathways, 885 diseases, and 208 pathological events, enabled us to identify the canonical network with the most significant relevance to the extracted network.

Results: Among 1,223 human miRNAs examined, Diana-microT 3.0 predicted reliable targets from 273 miRNAs. Among them, KeyMolnet successfully extracted molecular networks from 232 miRNAs. The most relevant pathway is transcriptional regulation by transcription factors RB/E2F, the disease is adult T cell lymphoma/leukemia, and the pathological event is cancer.

Conclusion: The predicted targets derived from approximately 20% of all human miRNAs constructed biologically meaningful molecular networks, supporting the view that a set of miRNA targets regulated by a single miRNA generally constitute the biological network of functionally-associated molecules in human cells.
Introduction

MicroRNAs (miRNAs) are a class of endogenous small noncoding RNAs conserved through the evolution. They mediate posttranscriptional regulation of protein-coding genes by binding to the 3’ untranslated region (3’UTR) of target mRNAs, leading to translational inhibition, mRNA destabilization or degradation, depending on the degree of sequence complementarity [1]. During the biogenesis of miRNAs, the primary miRNAs (pri-miRNAs) are transcribed from the intra- and inter-genetic regions of the genome by RNA polymerase II, followed by processing by the RNase III enzyme Drosha into pre-miRNAs. After nuclear export, they are cleaved by the RNase III enzyme Dicer into mature miRNAs consisting of approximately 22 nucleotides. Finally, a single-stranded miRNA is loaded onto the RNA-induced silencing complex (RISC), where the seed sequence located at positions 2 to 8 from the 5’ end of the miRNA plays a pivotal role in recognition of the target mRNA [2]. At present, more than one thousand of human miRNAs are registered in miRBase Release 16 http://www.mirbase.org. The 3’UTR of a single mRNA is often targeted by several different miRNAs, while a single miRNA concurrently reduces the production of hundreds of target proteins [3]. Consequently, the whole miRNA system (microRNAome) regulate greater than 60% of all protein-coding genes in a human cell [4]. By targeting multiple transcripts and affecting expression of numerous proteins, miRNAs play a key role in fine-tuning of diverse cellular functions, such as development, differentiation, proliferation, apoptosis and metabolism. Therefore, aberrant regulation of miRNA expression is deeply involved in pathological events that mediate cancers [5] and neurodegenerative disorders [6].

Recent advances in systems biology have made major breakthroughs by illustrating the cell-wide map of complex molecular interactions with the aid of the literature-based knowledgebase of molecular pathways [7]. The logically arranged molecular networks construct the whole system characterized by robustness, which maintains the proper function of the system in the face of genetic and environmental perturbations [8]. In the scale-free molecular network, targeted disruption of limited numbers of critical components designated hubs, on which the biologically important molecular interactions concentrate, efficiently disturbs the whole cellular function by destabilizing the network [9]. Therefore, the identification of the hub in the molecular network constructed by target genes of a particular miRNA helps us to understand biological and pathological roles of individual miRNAs. Recently, Hsu et al. studied the human microRNA-regulated protein-protein interaction (PPI) network by utilizing the Human Protein Reference Database (HPRD) and the miRNA target prediction program TargetScan [10]. They found that an individual miRNA often targets the hub gene of the PPI network, although they did not attempt to characterize relevant pathways, diseases, and pathological events regulated by miRNA target genes.

At present, the question remains to be fully elucidated whether a set of miRNA target genes regulated by an individual miRNA in the whole human microRNAome generally constitute the biological network of functionally-associated molecules or simply reflect a random set of functionally-independent genes. To address this question, we attempted to characterize molecular networks of target genes of all human miRNAs by using KeyMolnet, a bioinformatics tool for analyzing molecular interactions on the comprehensive knowledgebase.
Materials and methods

MicroRNA Target Prediction

The complete list of 1,223 human miRNAs was downloaded from miRBase Release 16 http://www.mirbase.org. We searched the target genes of individual miRNA on the Diana-microT 3.0 target prediction program (diana.cslab.ece.ntu.edu.tw/microT), which was selected because of the highest ratio of correctly predicted targets over other prediction tools [11]. Diana-microT 3.0 calculates the miRNA-targeted gene (miTG) score that reflects the weighted sum of the scores of all conserved and non-conserved miRNA recognition elements (MRE) on the 3'UTR of the target mRNA. The miTG score correlates well with fold changes in suppression of protein expression [11]. To optimize the parameter of miRNA-target interaction, we considered the target genes with a cutoff of the miTG score equal to or larger than 20 as the highly reliable targets, because we found that the targets with the miTG score < 20 exhibited significantly lower precision score, an indicator of correctness in predicted interactions [11], compared with those having the score \( \geq 20 \) (\( p = 2.78 \times 10^{-8} \) by Mann-Whitney’s U-test).

Molecular Network Analysis

Ensembl Gene IDs of target genes retrieved by Diana-microT 3.0 were converted into the corresponding Entrez Gene IDs by using the DAVID Bioinformatics Resources 6.7 program http://david.abcc.ncifcrf.gov[12], where non-annotated IDs were deleted. Then, Entrez Gene IDs of miRNA target genes were uploaded onto KeyMolnet. KeyMolnet is a tool for analyzing molecular interactions on the literature-based knowledgebase that contains the contents on 123,000 molecular relationships among human genes and proteins, small molecules, diseases, pathways and drugs, established by the Institute of Medicinal Molecular Design (IMMD) (Tokyo, Japan) [13-15]. The core contents are collected from selected review articles and textbooks with the highest reliability, regularly updated and carefully curated by a team of expert biologists. KeyMolnet contains a panel of human canonical networks constructed by core contents in the KeyMolnet library. They represent the gold standard of the networks, composed of 430 pathways, 885 diseases, and 208 pathological events. Detailed information on all the contents is available from IMMD http://www.immd.co.jp/en/keymolnet/index.html upon request.

We utilized the neighboring network-search algorithm that selects the set of miRNA target genes as starting points to generate the network around starting points within one path, composed of all kinds of molecular interactions, including direct activation/inactivation, transcriptional activation/repression, and the complex formation. By uploading the list of Entrez Gene IDs onto KeyMolnet, it automatically provides corresponding molecules and a minimum set of intervening molecules as a node on networks. The generated network was compared side by side with human canonical networks described above. The algorithm that counts the number of overlapping molecules and/or molecular relations between the extracted network and the canonical network identifies the canonical network showing the most statistically significant contribution to the extracted network. This algorithm is essentially based on that of the GO::TermFinder [16]. The significance in the similarity between the extracted network and the canonical network is scored following the formula, where \( O = \) the number of overlapping molecules and molecular relations for the pathway or overlapping molecules alone for the disease and the pathological event between the extracted network and the canonical network, \( V = \) the number of molecules
and/or molecular relations located in the extracted network, \( C = \) the number of molecules and/or molecular relations located in the canonical network, \( T = \) the number of total molecules and/or molecular relations of KeyMolnet, currently composed of approximately 15,700 molecules and 123,000 molecular relations, and the \( \times = \) the sigma variable that defines coincidence.

\[
\text{Score} = -\log_2 (\text{Score (p)}) \quad \text{Score (p)} = \sum_{x=0}^{\min(C,V)} f(x) \quad f(x) = cC_x \cdot \frac{T - C_CV - x}{T_CV} \quad (1)
\]

Results

Molecular Network of MicroRNA Target Genes

Among 1,223 human miRNAs examined, Diana-microT 3.0 predicted the targets from 532 miRNAs (43.5%). Among the 532 miRNAs, 273 miRNAs contained a set of highly reliable targets showing the miTG score \( \geq 20 \). Among 273 miRNAs having reliable targets, KeyMolnet successfully extracted molecular networks from 232 miRNAs. They are comprised of 19% of total human miRNAs (microRNAome). Then, the generated network was compared side by side with human canonical networks of the KeyMolnet library, composed of 430 pathways, 885 diseases, and 208 pathological events. We found that not all 232 miRNAs contained entire categories of canonical networks because several miRNAs comprised relatively small numbers of targets. See Additional file 1 for all the information on 232 miRNAs and their target networks. When top three pathways, diseases, and pathological events were individually totalized, the most relevant pathway is ‘transcriptional regulation by RB/E2F’ (n = 39; 6.8% of total), followed by ‘TGF-beta family signaling pathway’ (n = 32; 5.6%) and ‘transcriptional regulation by POU domain factor’ (n = 24; 4.2%), the most relevant disease is ‘adult T cell lymphoma/leukemia’ (n = 68; 12.1%), followed by ‘chronic myelogenous leukemia’ (n = 65; 11.5%) and ‘hepatocellular carcinoma’ (n = 51; 9.1%), and the most relevant pathological event is ‘cancer’ (n = 97; 24.7%), followed by ‘adipogenesis’ (n = 46; 11.7%) and ‘metastasis’ (n = 36; 9.2%) (Figure 1 and Additional file 1).

Next, we identified the large-scale miRNA target networks by uploading targets greater than 100 per individual miRNA onto KeyMolnet (Table 1). Fifty-two miRNAs that construct such a large-scale miRNA target network include let-7, miR-9, 17, 19, 20, 26, 27, 29, 30, 32, 92, 93, 96, 98, 101, 106b, 124, 137, 147, 153, 218, 372, 429, 495, 506, 519, 520, 603, and their closely-related family members. The targets of these miRNAs established highly complex molecular networks, in which the pathways of ‘transcriptional regulation by RB/E2F’, ‘transcriptional regulation by Ets-domain family’, and ‘transcriptional regulation by p53’, the diseases of ‘chronic myelogenous leukemia’ and ‘viral myocarditis’, and the pathological event of ‘cancer’ were notably accumulated (Table 1). Importantly, distinct members belonging to the same miRNA family, for example, five miR-30 family members ranging from miR-30a to miR-30e constructed a virtually identical molecular network (Table 1).

Biological Implications of MicroRNA Target Networks

As described above, the present observations indicated that a set of miRNA target genes regulated by an individual miRNA generally constitute the biological network of
functionally-associated molecules in human cells. Therefore, it is highly important to obtain deeper insights into biological implications of miRNA target networks.

The protooncogene c-myb is a key transcription factor for normal development of hematopoietic cells. A recent study showed that miR-15a targets c-myb, while c-myb binds to the promoter of miR-15a, providing an autoregulatory feedback loop in human hematopoietic cells [17]. Consistent with this study, we found ‘transcriptional regulation by myb’ as the most relevant pathway to the miR-15a target network (the score = 602; the score p-value = 7.39E-182) (Figure 2 and Additional file 1). These observations propose a scenario that miR-15a synchronously downregulates both c-myb itself and downstream genes transcriptionally regulated by c-myb, resulting in

Figure 1 The pathways, diseases, and pathological events relevant to 232 miRNA target networks
Among 1,223 human miRNAs examined, Diana-microT 3.0 identified the set of reliable targets from 273 miRNAs. Among them, KeyMolnet extracted molecular networks from 232 miRNAs. The generated network was compared side by side with human canonical networks of the KeyMolnet library, composed of 430 pathways, 885 diseases, and 208 pathological events to identify the canonical network showing the most statistically significant contribution to the extracted network (see Table S1 for all the information). After top three pathways, diseases, and pathological events were individually totaled, the cumulated numbers of top 10 of (a) pathway, (b) disease, and (c) pathological event categories are expressed as a bar graph.
Table 1 The large-scale human microRNA target networks

| MicroRNA | Number of Targets | Molecules in KeyMolNet Networks | Top Pathway Score | p-Value | Top Disease Score | p-Value | Top Pathological Event Score | p-Value |
|----------|------------------|---------------------------------|-------------------|---------|------------------|---------|-------------------------------|---------|
| hsa-let-7a | 244              | 1022                            | Transcriptional regulation by p53 | 593     | 2.69E-179        | Viral myocarditis | 113   | 1.21E-34                     | Cancer  |
| hsa-let-7b | 242              | 1016                            | Transcriptional regulation by p53 | 594     | 1.83E-179        | Viral myocarditis | 113   | 9.32E-35                     | Cancer  |
| hsa-let-7c | 243              | 1020                            | Transcriptional regulation by p53 | 593     | 2.49E-179        | Viral myocarditis | 113   | 1.11E-34                     | Cancer  |
| hsa-let-7d | 145              | 885                             | Transcriptional regulation by RB/E2F | 836    | 2.18E-252        | Chronic myelogenous leukemia | 72   | 1.95E-22                     | Cancer  |
| hsa-let-7e | 236              | 1111                            | Transcriptional regulation by RB/E2F | 575    | 8.90E-174        | Viral myocarditis | 116   | 1.20E-35                     | Cancer  |
| hsa-let-7f | 244              | 1022                            | Transcriptional regulation by p53 | 593     | 2.69E-179        | Viral myocarditis | 113   | 1.21E-34                     | Cancer  |
| hsa-let-7g | 245              | 1022                            | Transcriptional regulation by p53 | 593     | 2.69E-179        | Viral myocarditis | 113   | 1.21E-34                     | Cancer  |
| hsa-let-7i | 245              | 1022                            | Transcriptional regulation by p53 | 593     | 2.69E-179        | Viral myocarditis | 113   | 1.21E-34                     | Cancer  |
| hsa-miR-9  | 352              | 1115                            | Transcriptional regulation by RB/E2F | 340    | 5.28E-103        | Hepatocellular carcinoma | 72   | 1.69E-22                     | Cancer  |
| hsa-miR-17 | 195              | 961                             | Transcriptional regulation by RB/E2F | 971    | 3.27E-293        | Chronic myelogenous leukemia | 92   | 2.83E-28                     | Cancer  |
| hsa-miR-19a| 226              | 1094                            | Transcriptional regulation by RB/E2F | 760    | 2.10E-229        | Chronic myelogenous leukemia | 113  | 1.26E-34                     | Cancer  |
| hsa-miR-19b| 225              | 1094                            | Transcriptional regulation by RB/E2F | 760    | 2.10E-229        | Chronic myelogenous leukemia | 113  | 1.26E-34                     | Cancer  |
| hsa-miR-20a| 165              | 1038                            | Transcriptional regulation by RB/E2F | 856    | 1.64E-258        | Chronic myelogenous leukemia | 87   | 6.09E-27                     | Cancer  |
| hsa-miR-20b| 198              | 981                             | Transcriptional regulation by RB/E2F | 962    | 2.35E-200        | Chronic myelogenous leukemia | 98   | 3.39E-30                     | Cancer  |
| hsa-miR-26a| 148              | 672                             | Transcriptional regulation by RB/E2F | 919    | 1.76E-277        | Chronic myelogenous leukemia | 107  | 6.15E-33                     | Cancer  |
| hsa-miR-26b| 148              | 672                             | Transcriptional regulation by RB/E2F | 919    | 1.76E-277        | Chronic myelogenous leukemia | 107  | 6.15E-33                     | Cancer  |
| hsa-miR-27a| 229              | 1192                            | Transcriptional regulation by CREB | 1022   | 2.23E-308        | Chronic myelogenous leukemia | 95   | 1.96E-29                     | Cancer  |
| hsa-miR-27b| 261              | 1337                            | Transcriptional regulation by CREB | 1022   | 2.23E-308        | Chronic myelogenous leukemia | 94   | 4.51E-29                     | Cancer  |
| hsa-miR-29a| 119              | 543                             | Transcriptional regulation by Ets-domain family | 430    | 4.36E-130        | Glioma                  | 85   | 3.46E-26                     | Cancer  |
| miRNA | Count | Score | Action | Gene | Tissue | Disease | Count | Score |
|-------|-------|-------|--------|------|--------|---------|-------|-------|
| hsa-miR-29b | 118 | 578 | Transcriptional regulation by Ets-domain family | | | | 422 | 1.15E-127 |
| hsa-miR-29c | 118 | 543 | Transcriptional regulation by Ets-domain family | | | | 430 | 4.36E-130 |
| hsa-miR-30a | 455 | 1494 | Transcriptional regulation by RB/E2F | | | | 777 | 9.43E-235 |
| hsa-miR-30b | 455 | 1480 | Transcriptional regulation by RB/E2F | | | | 781 | 1.08E-235 |
| hsa-miR-30c | 454 | 1495 | Transcriptional regulation by RB/E2F | | | | 778 | 6.13E-235 |
| hsa-miR-30d | 452 | 1491 | Transcriptional regulation by RB/E2F | | | | 778 | 7.28E-235 |
| hsa-miR-31 | 261 | 905 | Transcriptional regulation by RB/E2F | | | | 842 | 2.74E-254 |
| hsa-miR-92a | 219 | 642 | Transcriptional regulation by MEF2 | | | | 335 | 1.51E-101 |
| hsa-miR-92b | 258 | 701 | Transcriptional regulation by MEF2 | | | | 328 | 1.59E-99 |
| hsa-miR-93 | 195 | 958 | Transcriptional regulation by MEF2 | | | | 972 | 2.37E-293 |
| hsa-miR-96 | 142 | 688 | Transcriptional regulation by Ets-domain family | | | | 407 | 3.42E-123 |
| hsa-miR-98 | 162 | 671 | Transcriptional regulation by Myb | | | | 549 | 4.73E-166 |
| hsa-miR-101 | 188 | 806 | Transcriptional regulation by AP-1 | | | | 492 | 1.10E-148 |
| hsa-miR-106b | 164 | 1028 | Transcriptional regulation by RB/E2F | | | | 854 | 7.21E-258 |
| hsa-miR-124 | 285 | 1346 | Transcriptional regulation by RB/E2F | | | | 756 | 3.57E-228 |
| hsa-miR-137 | 288 | 941 | Transcriptional regulation by MITF family | | | | 339 | 1.19E-102 |
| hsa-miR-147 | 199 | 867 | Transcriptional regulation by RB/E2F | | | | 805 | 4.06E-243 |
| hsa-miR-153 | 154 | 1019 | Transcriptional regulation by Myb | | | | 507 | 2.35E-153 |

Satoh and Tabunoki BioData Mining 2011, 4:17
http://www.biodatamining.org/content/4/1/17
Page 7 of 13
efficient inactivation of the whole molecular network governed by the hub gene c-myb. These results suggest a collaborative regulation of gene expression at both transcriptional and posttranscriptional levels that involve coordinated regulation by miRNAs and transcription factors.

The retinoblastoma protein Rb/E2F pathway acts as a gatekeeper for G1/S transition in the cell cycle. The Rb/E2F-regulated G1 checkpoint control is often disrupted in cancer cells. A recent study showed that miR-106b is directly involved in posttranscriptional regulation of E2F1 [18]. E2F1 activates transcription of miR-106b, while miR-

Table 1 The large-scale human microRNA target networks (Continued)

| miRNA   | Target Count | Target | Regulation by          | Disease       | Score   | Significance   |
|---------|--------------|--------|------------------------|---------------|---------|----------------|
| hsa-miR-218 | 155         | 830    | Transcriptional         | Hepatocellular carcinoma | 344     | 2.28E-104     |
|         |              |        | regulation by AP-1     |               |         |                |
| hsa-miR-372 | 101         | 562    | Transcriptional         | Chronic myelogenous leukemia | 1022    | 2.23E-308     |
|         |              |        | regulation by RB/E2F   |               |         |                |
| hsa-miR-429 | 123         | 634    | Transcriptional         | Chronic myelogenous leukemia | 918     | 2.45E-277     |
|         |              |        | regulation by RB/E2F   |               |         |                |
| hsa-miR-495 | 156         | 601    | Transcriptional         | Rheumatoid arthritis | 431     | 2.14E-130     |
|         |              |        | regulation by Ets-domain family |             |         |                |
| hsa-miR-506 | 394         | 1536   | Transcriptional         | Viral myocarditis | 317     | 4.69E-96      |
|         |              |        | regulation by Ets-domain family |             |         |                |
| hsa-miR-519a | 281        | 1256   | Transcriptional         | Chronic myelogenous leukemia | 811     | 5.32E-245     |
|         |              |        | regulation by RB/E2F   |               |         |                |
| hsa-miR-519b-3p | 281  | 1256   | Transcriptional         | Chronic myelogenous leukemia | 811     | 5.32E-245     |
|         |              |        | regulation by RB/E2F   |               |         |                |
| hsa-miR-519c-3p | 281  | 1256   | Transcriptional         | Chronic myelogenous leukemia | 811     | 5.32E-245     |
|         |              |        | regulation by RB/E2F   |               |         |                |
| hsa-miR-520a-3p | 184  | 690    | Transcriptional         | Chronic myelogenous leukemia | 1022    | 2.23E-308     |
|         |              |        | regulation by RB/E2F   |               |         |                |
| hsa-miR-520b | 182         | 690    | Transcriptional         | Chronic myelogenous leukemia | 1022    | 2.23E-308     |
|         |              |        | regulation by RB/E2F   |               |         |                |
| hsa-miR-520c-3p | 182  | 690    | Transcriptional         | Chronic myelogenous leukemia | 1022    | 2.23E-308     |
|         |              |        | regulation by RB/E2F   |               |         |                |
| hsa-miR-520d-3p | 183  | 690    | Transcriptional         | Chronic myelogenous leukemia | 1022    | 2.23E-308     |
|         |              |        | regulation by RB/E2F   |               |         |                |
| hsa-miR-520e | 184         | 690    | Transcriptional         | Chronic myelogenous leukemia | 1022    | 2.23E-308     |
|         |              |        | regulation by RB/E2F   |               |         |                |
| hsa-miR-603 | 252         | 1150   | Transcriptional         | Multiple myeloma | 344     | 3.26E-104     |
|         |              |        | regulation by Ets-domain family |             |         |                |

Among 1,223 human miRNAs examined, Diana-microT 3.0 predicted reliable targets from 273 miRNAs. Among them, KeyMolnet extracted molecular networks from 232 miRNAs. The generated network was compared side by side with human canonical networks of the KeyMolnet library, composed of 430 pathways, 885 diseases, and 208 pathological events. The canonical pathways, diseases, and pathological events with the most statistically significant contribution to the extracted network are shown. The table contains only the large-scale miRNA target networks generated by importing targets greater than 100 per individual miRNA into KeyMolnet. See Additional file 1 for all the information on 232 miRNAs and their target networks.

Satoh and Tabunoki BioData Mining 2011, 4:17
http://www.biomedcentral.com/content/4/1/17
106b targets E2F1, serving as a miRNA-directed negative feedback loop in gastric cancer cells [18]. Supporting these findings, we identified ‘transcriptional regulation by Rb/E2F’ as the most relevant pathway to the miR-106b target network (the score = 854; the score p-value = 7.21E-258) (Figure 3, Table 1 and Additional file 1). The relationship between miR-106b and Rb/E2F would provide another example of coordinated regulation of gene expression by miRNAs and transcription factors.

We found ‘transcriptional regulation by p53’ as the most relevant pathway to the target network of all let-7 family members except for let-7d (Table 1). It is worthy to note that the tumor suppressor p53 regulates the expression of components of the miRNA-processing machinery, such as Drosha, DGC88, Dicer, and TARBP2, all of which have p53-responsive elements in their promoters [19]. Furthermore, Dicer and TARBP2, along with p53, serve as a target of the let-7 family miRNAs, suggesting a close link between p53 and let-7 in miRNA biogenesis [19]. The expression of let-7 family members was greatly reduced in certain cancer cells [20].

The microphthalmia associated transcription factor (MITF), a basic helix-loop-helix zipper (bHLH-Zip) transcription factor, acts as not only a master regulator of melanocyte differentiation but also an oncogene promoting survival of melanoma. Recent studies indicate that MITF is a direct target of both miR-137 and miR-148b [21,22]. Again, we identified ‘transcriptional regulation by MITF family’ as the most relevant pathway to both miR-137 (the score = 339; the score p-value = 1.19E-102) and miR-
148b (the score = 40; the score p-value = 3.91E-142) target networks (Table 1 and Additional file 1).

Cellular responsiveness to glucocorticoids (GCs) is regulated by the delicate balance of the glucocorticoid receptor (GR) protein, GR coactivators and corepressors, GR splice variants and isoforms, and regulators of GR retrograde transport to the nucleus. A recent study showed that miR-18a targets the GR protein, and thereby inhibits GR-mediated biological events in neuronal cells [23]. Consistent with this, we found ‘transcriptional regulation by GR’ as the most relevant pathway to the miR-18a target network (the score = 1022; the score p-value = 2.23E-308) (Additional file 1).

Zinc finger transcription factors ZEB1 and ZEB2 act as a transcriptional repressor of E-cadherin. A recent study showed that miR-200b, which targets both ZEB1 and ZEB2, was downregulated in the cells that undergo TGF-beta-induced epithelial to mesenchymal transition (EMT), and was lost in invasive breast cancer cells [24]. We identified ‘transcriptional regulation by ZEB’ as the third-rank significant pathway (the score = 155; the score p-value = 1.88E-47) and ‘EMT’ as the third-rank significant pathological event relevant to the miR-200b target network (the score = 61; the score p-value = 4.15E-19) (Additional file 1).

**Discussion**

In general, a single miRNA concurrently downregulates hundreds of target mRNAs by binding to the corresponding 3'UTR of mRNA via either perfect or imperfect sequence complementarity [3]. Such fuzzy mRNA-miRNA interactions result in the redundancy
of miRNA-recognized targets. By targeting multiple transcripts and affecting expression of numerous proteins at one time, miRNAs regulate a wide range of cellular functions, such as development, differentiation, proliferation, apoptosis and metabolism. Therefore, we have the question whether a set of miRNA target genes regulated by an individual miRNA generally constitute the biological network of functionally-associated molecules or simply reflect a random set of functionally-independent genes. If the former is the case, what kind of biological networks does the human microRNAome most actively regulates?

To address these questions, first we identified the set of credible target genes for all individual human miRNAs by using the Diana-microT 3.0 program. Then, we investigated miRNA target networks by applying them to KeyMolnet, a bioinformatics tool for analyzing molecular interactions on the comprehensive knowledgebase. Diana-microT 3.0 identified highly reliable targets from 273 miRNAs out of 1,223 all human miRNAs. Previous studies showed that the list of predicted targets for each miRNA varies among different miRNA target prediction programs armed with distinct algorithms, such as TargetScan 5.1 http://www.targetscan.org, PicTar (pictar.mdc-berlin.de), miRanda http://www.microrna.org and Diana-microT 3.0 [25]. Therefore, miRNA target networks are to some extent flexible, depending on the target prediction program employed. Among the programs described above, we have chosen Diana-microT 3.0 because of the highest ratio of correctly predicted targets over other prediction tools and the simplicity of setting a cut-off point for detection of reliable miRNA-target interactions based on the miTG score [11].

Here we found that highly reliable targets of substantial numbers of human miRNAs actually constructed biologically meaningful molecular networks. These observations strongly supported the theoretical view that miRNA target genes regulated by an individual miRNA in the whole human microRNAome generally constitute the biological network of functionally-associated molecules. A recent study showed that interacting proteins in the human PPI network tend to share restricted miRNA target-site types than random pairs, being consistent with our observations [26].

We also found that there exists a coordinated regulation of gene expression at the transcriptional level by transcription factors and at the posttranscriptional level by miRNAs in miRNA target networks. Recently, Cui et al. investigated the relationship between miRNA and transcription factors in gene regulation [27]. Importantly, they found that the genes with more transcription factor-binding sites have a higher probability of being targeted by miRNAs and have more miRNA-binding sites.

A recent study by miRNA expression profiling of thousands of human tissue samples revealed that diverse miRNAs constitute a complex network composed of coordinately regulated miRNA subnetworks in both normal and cancer tissues, and they are often disorganized in solid tumors and leukemias [28]. During carcinogenesis, various miRNAs play a central role, acting as either oncogenes named oncomir or tumor suppressors termed anti-oncomir, by targeting key molecules involved in apoptosis, cell cycle, cell adhesion and migration, chromosome stability, and DNA repair [5]. Many miRNA gene loci are clustered in cancer-associated genomic regions [29]. Furthermore, miRNA expression signatures well discriminate different types of cancers with distinct clinical prognoses [30]. In the present study, KeyMolnet analysis of miRNA target networks showed that the most relevant pathological event is ‘cancer’, when top three
pathological events were overall cumulated. Furthermore, the highly relevant diseases include ‘adult T cell lymphoma/leukemia’, ‘chronic myelogenous leukemia’, and ‘hepatocellular carcinoma’. These observations suggest that the human microRNAome plays a more specialized role in regulation of oncogenesis. Therefore, the miRNA-based therapy directed to targeting multiple cancer-associated pathways simultaneously might serve as the most effective approach to suppressing the oncogenic potential of a wide range of cancers.

**Conclusion**

The reliable targets predicted by Diana microT 3.0 derived from approximately 20% of all human miRNAs constructed biologically meaningful molecular networks by KeyMolnet. These observations support the view that miRNA target genes regulated by an individual miRNA in the whole human microRNAome generally constitute the biological network of functionally-associated molecules. In the human miRNA target networks, the most relevant pathway is transcriptional regulation by transcription factors RB/E2F, the disease is adult T cell lymphoma/leukemia, and the pathological event is cancer. In miRNA target networks, there exists a coordinated regulation of gene expression at the transcriptional level by transcription factors and at the posttranscriptional level by miRNAs.

**Additional material**

Additional file 1: KeyMolnet identifies microRNA target networks in 232 human miRNAs. The prediction of target genes of individual miRNA was performed by Diana-microT 3.0. Entrez Gene IDs of miRNA target genes were uploaded onto KeyMolnet. The generated network was compared side by side with human canonical networks composed of 430 pathways, 885 diseases, and 208 pathological events of the KeyMolnet library. Top-three pathways, diseases, and pathological events with the statistically significant contribution to the extracted network are shown.

**Acknowledgements**

This work was supported by grants from the Research on Intractable Diseases (H22-Nanchi-Ippan-136), the Ministry of Health, Labour and Welfare (MHLW), Japan and the High-Tech Research Center Project (S0801043) and the Grant-in-Aid (C22500322), the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan.

**Authors’ contributions**

JS designed the methods, analyzed the data, and drafted the manuscript. HT helped the data analysis. All authors have read and approved the final manuscript.

**Competing interests**

The authors declare that they have no competing interests.

Received: 13 October 2010 Accepted: 17 June 2011 Published: 17 June 2011

**References**

1. Guo H, Ingolia NT, Weissman JS, Bartel DP: Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010, 466:835-40.
2. Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-33.
3. Selbach M, Schwanhäusser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N: Widespread changes in protein synthesis induced by microRNAs. Nature 2008, 455:58-63.
4. Friedman RC, Farh KK, Burge CB, Bartel DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009, 19:92-105.
5. Garzon R, Marcucci G, Croce CM: Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010, 9:775-89.
6. Shioya M, Ohyashiki S, Tabunoki H, Arima K, Saito Y, Ishida T, Satoh J: Aberrant microRNA expression in the brains of neurodegenerative diseases: miR-29a decreased in Alzheimer disease brains targets neurone navigator 3. Neuropathol Appl Neurobiol 2010, 36:520-30.
7. Viswanathan GA, Sato J, Pasti S, Nudelman G, Sealfon SC: Getting started in biological pathway construction and analysis. PLoS Comput Biol 2008, 4:e16.
8. Kitano H. A robustness-based approach to systems-oriented drug design. *Nat Rev Drug Discov* 2007, 6:202-10.
9. Albert R, Jeong H, Barabási AL. Error and attack tolerance of complex networks. *Nature* 2000, 406:378-82.
10. Hsu CW, Juan HF, Huang HC. Characterization of microRNA-regulated protein–protein interaction network. *Proteomics* 2008, 8:1975-9.
11. Maragakis M, Alexiou P, Papadopoulos GL, Rezzico M, Dalamagas T, Giannopoulos G, Gounis M, Koulis E, Kourtis K, Simopoulou A, Spathopoulos P, Vergoulis T, Kostris N, Selli S, Tsaknakis P, Hatziigiou AG. Accurate microRNA target prediction correlates with protein repression levels. *BMC Bioinformatics* 2009, 10:295.
12. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat Protoc* 2009, 4:44-57.
13. Sato H, Ishida S, Toda K, Matsuura R, Hayashi Y, Shigeta M, Fukuda M, Wakahama Y, Itai A. New approaches to mechanism analysis for drug discovery using DNA microarray data combined with KeyMolNet. *Curr Drug Discov Technol* 2005, 2:89-98.
14. Satoh J, Tabunoki H, Yamamura T. Molecular network of the comprehensive multiple sclerosis brain-lesion proteome. *Mult Scler* 2009, 15:531-41.
15. Satoh J, Tabunoki H, Arima K. Molecular network analysis suggests aberrant CREB-mediated gene regulation in the Alzheimer disease hippocampus. *Dis Markers* 2009, 27:239-52.
16. Boyle EI, Weng S, Gollub J, Jin H, Botstein D, Cherry JM, Sherlock G. GO:TermFinder-open source software for accessing Gene Ontology information and finding significantly enriched Gene Ontology terms associated with a list of genes. *Bioinformatics* 2004, 20:3770-15.
17. Zhao H, Kalota A, Jin S, Gewirtz AM. The c-mycb proto-oncogene and microRNA-15a comprise an active autoregulatory feedback loop in human hematopoietic cells. *Blood* 2009, 113:505-16.
18. Petracca F, Visone R, Orelli MR, Shah MH, Nicolosi MS, de Martino L, Iliopoulos D, Pilozzi E, Liu CG, Negrini M, Cavazza L, Volinia S, Galasso M, Costinean S, Tagliavini L, Gamberoni G, Drusco A, Marchesini J, Mascellani N, Sana ME, Abu Jarour R, Tassone D, Cattaneo E, Baffa R, Aqeilan R, Iorio MV, Taccioli C, Garzon R, Di Leva G, Fabbri M, Catozzi M, Jonge J, Kamphorst JT, Barbosa JS, Zweers T, Champagne DL, Schouten T, Meijer OC, Premont EJ, Wymenga AB, Kipps TJ, Huebner K, Pichiorri F, Linzen D, Cairo S, Buendia MA, Kiss-Laszlo ZS, Di Leva G, Catalano F, Gualberto A, Gasparini P, Harris CC, Visone R, Pekarsky Y, de la Chapelle A, Bloomston M, Rassenti LZ, Kipps TJ, Huebner K, Pichiorri F, Linzen D, Cairo S, Buendia MA, Paino P, Dejean A, Zanesi N, Rossi S, Calin GA, Liu CG, Palatini J, Negrini M, Vecchione A, Rosenberg A, Croce CM. Reprogramming of miRNA networks in cancer and leukemia. *Genome Res* 2010, 20:589-99.
19. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. *Proc Natl Acad Sci USA* 2004, 101:2999-3004.
20. Lu Ji, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR. MicroRNA expression profiles classify human cancers. *Nature* 2005, 435:834-38.

Cite this article as: Satoh and Tabunoki. Comprehensive analysis of human microRNA target networks. *BioData Mining* 2011, 4:17.

doi:10.1186/1756-0381-4-17